Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;36(2):566-568.
doi: 10.1038/s41375-021-01410-2. Epub 2021 Sep 8.

RBC distribution width predicts thrombosis risk in polycythemia vera

Dan Liu  1   2 , Bing Li  1   2 , Zefeng Xu  1   2 , Peihong Zhang  1   3 , Tiejun Qin  1   2 , Shiqiang Qu  1   2 , Lijuan Pan  1   2 , Xiujuan Sun  1 , Zhongxun Shi  1   2 , Huijun Huang  1   2 , Huijun Wang  1   3 , Robert Peter Gale  4 , Zhijian Xiao  5   6   7
Affiliations

RBC distribution width predicts thrombosis risk in polycythemia vera

Dan Liu et al. Leukemia. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; advisor to Antegene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Percentage of patients with thrombosis and thrombosis-free survivals.
Comparison of percentage of patients with thrombosis between Chinese and persons of predominately European descent pre- (A) and post-diagnosis (B)2 and in low-risk cohorts post-diagnosis (C)15. Prognostic value of RDW for TFS (D). RDW < 14.5% is associated with worse TFS in high-risk subjects defined by standard criteria (E), subjects ≥50 years (F) and with prior thrombosis (G). Predictive value of RDW for arterial TFS (H). New model for TFS including age ≥ 68 years (2 point), age 50–67 years (1 point) and RDW < 14.5% (1 point): low-risk (0 or 1 point; 5-year cumulative incidence [CI] of thrombosis: 3.9% [3.0, 4.8]); high-risk (≥2 points; 5-year CI of thrombosis: 10.4% [7.6, 13.2]) (I). Barbui et al. [2], median follow-up 6.9 years (range, 0–39 years; n = 1545). Barbui et al. [10], median follow-up 4.9 years (range, 0–34 years) in low-risk subjects treated by phlebotomy (n = 604). CI cumulative incidence, TFS thrombosis-free survival; **p < 0.01; *** p < 0.001.
See this image and copyright information in PMC

References

    1. Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7:662. doi: 10.1038/s41408-017-0035-6. - DOI - PMC - PubMed
    1. Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124:1822. doi: 10.1182/blood.V124.21.1822.1822. - DOI - PubMed
    1. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–24. doi: 10.1056/NEJMoa035572. - DOI - PubMed
    1. De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018;8:112. doi: 10.1038/s41408-018-0151-y. - DOI - PMC - PubMed
    1. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia. 2007;21:1952–59. doi: 10.1038/sj.leu.2404854. - DOI - PubMed

Publication types